Results for this period
Full year1 April 2025–31 March 2026Non-consolidated (standalone)Japanese GAAPThe width of the band at each stage is based on revenue. The narrower it becomes toward the bottom, the smaller the proportion of revenue that remains as profit. The dotted outline is the full-year forecast and the band inside it is the result for this period. The progress rate is the result divided by the forecast.
塗りつぶした部分が自己資本比率です。総資産のうち、返済のいらない自前の資金がどれだけかを表します。The thin vertical line indicates the level at the end of the previous fiscal year.
Stacked from zero: upward is an increase in cash, downward a decrease (in Millions of yen).The net change represented by the dotted line is the total of three items, calculated from figures provided by the company.
Net sales increased as a result of meeting strong demand for each product. Profitability deteriorated in the fourth quarter due to the first-year depreciation burden for amino acid-related facilities, as well as the rapid decline in market prices and market share for certain products for electronic materials.
No applicable matters
| Item | Details |
|---|---|
| Fiscal Period Classification | Full year |
| Accounting standards | Japanese GAAP |
| Consolidated / non-consolidated | Non-consolidated (standalone) |
| Period Covered | 1 April 2025–31 March 2026 |
| Net Sales | 15,448 Millions of yen (YoY +2.1%) |
| Operating profit | 383 Millions of yen (YoY -68.4%) |
| Ordinary income | 303 Millions of yen (YoY -73.4%) |
| Profit attributable to owners of the parent | 313 Millions of yen (YoY -65.1%) |
| Net income per share | ¥14.51 |
| Operating Margin | 2.5% |
| Equity ratio | End of the current fiscal period 52.4% / End of previous period 48.8% |
| Total assets | 25,730 Millions of yen |
| Net assets | 13,487 Millions of yen |
| Cash flows from operating activities | 2,844 Millions of yen |
| Cash flows from investing activities | -1,008 Millions of yen |
| Cash flows from financing activities | -1,922 Millions of yen |
| Cash and cash equivalents at end of period | 885 Millions of yen |
| Full-year earnings forecast | Net Sales 16,000 Millions of yen (YoY +3.6%) / Operating profit To be determined / Ordinary income To be determined / Net income To be determined |
| Annual Dividend Forecast | 9 yen and sen → 10 yen and sen（+11.1%） |
| Payout ratio | 68.9% |
| Regional sales | Region Domestic / Current fiscal year 7,429 Millions of yen / Previous period 7,591 Millions of yen, Region Exports / Current fiscal year 8,018 Millions of yen / Previous period 7,536 Millions of yen |
| Depreciation and amortization | 1,238 Millions of yen |
| Breakdown of extraordinary income (loss) | Extraordinary income Government subsidies 1,854 Millions of yen, Gain on sale of investment securities 60 Millions of yen / Extraordinary loss Loss on Disposal of Fixed Assets 47 Millions of yen, Loss on reduction of fixed assets 1,809 Millions of yen |
| Disclosure regarding the going concern assumption | No applicable matters |
| Change in accounting policy | Changes due to revisions to standards No / Other changes No / Change in accounting estimate No / Restatement No |
| Material subsequent events | No applicable matters. |
| Availability of Supplementary Financial Results Materials | No |
| Availability of Financial Results Briefing | Held (対象者：Not disclosed) |
| Issued Shares at Period-End | 21,974,000 Shares |
| Treasury Shares at Period-End | 360,354 Shares |
| Factors Behind Changes in Business Performance | Net sales increased as a result of meeting strong demand for each product. Profitability deteriorated in the fourth quarter due to the first-year depreciation burden for amino acid-related facilities, as well as the rapid decline in market prices and market share for certain products for electronic materials. |
Items this document does not state (7)
These are items the company does not state in this document. We do not leave them blank, nor fill them in from other sources or by inference.
The reasons the company gives
The company's own explanation, not something inferred from the numbers.This was because the company incurred depreciation expenses for the first year on amino acid-related facilities completed in June 2025, while market prices and market share for certain products for electronic materials declined rapidly, worsening profitability in the fourth quarter. The earnings forecast for the fiscal year ending March 2027 remains undecided because it is difficult at present to reasonably calculate the impact of the situation in the Middle East on the business, among other reasons.